Aminopeptidase N as a potential drug target

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14160%2F23%3A00133779" target="_blank" >RIV/00216224:14160/23:00133779 - isvavai.cz</a>

Výsledek na webu

<a href="https://sciendo.com/issue/AFPUC/0/0" target="_blank" >https://sciendo.com/issue/AFPUC/0/0</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.2478/afpuc-2024-0002" target="_blank" >10.2478/afpuc-2024-0002</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Aminopeptidase N as a potential drug target

Popis výsledku v původním jazyce

Aminopeptidase N (APN) is a broad specificity zinc metallopeptidase with many functions that do not always depend on its enzymatic activity. Among others, it is involved in tumor angiogenesis and metastasizing and also serves as a cellular receptor of some coronaviruses. Some APN inhibitors, such as bestatin or tosedostat, were used or tested as anticancer drugs in the past. Within the past two decades, we have prepared several series of potential APN inhibitors. Some of them reached interesting values of inhibitory activity and were also successfully tested for antiproliferation activity in cancer cell lines. We also performed some QSAR studies with APN inhibitors prepared by us and other authors.

Název v anglickém jazyce

Aminopeptidase N as a potential drug target

Popis výsledku anglicky

Aminopeptidase N (APN) is a broad specificity zinc metallopeptidase with many functions that do not always depend on its enzymatic activity. Among others, it is involved in tumor angiogenesis and metastasizing and also serves as a cellular receptor of some coronaviruses. Some APN inhibitors, such as bestatin or tosedostat, were used or tested as anticancer drugs in the past. Within the past two decades, we have prepared several series of potential APN inhibitors. Some of them reached interesting values of inhibitory activity and were also successfully tested for antiproliferation activity in cancer cell lines. We also performed some QSAR studies with APN inhibitors prepared by us and other authors.

Druh

J_ost - Ostatní články v recenzovaných periodicích

CEP obor

—

OECD FORD obor

30107 - Medicinal chemistry

Projekt

—

Návaznosti

S - Specificky vyzkum na vysokych skolach<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2023

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

European Pharmaceutical Journal

ISSN

2453-6725

e-ISSN

1338-6786

Svazek periodika

70

Číslo periodika v rámci svazku

s2

Stát vydavatele periodika

SK - Slovenská republika

Počet stran výsledku

2

Strana od-do

„AoP,1“-„2“

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—